Servier to Acquire Day One Biopharmaceuticals in a $2.5 Billion Cash Deal

France’s Servier entered a merger agreement on March 6, 2026, to acquire Day One Biopharmaceuticals, Inc. (DAWN) in an all-cash deal valued at $2.5 billion.

Deal Structure:

Servier will commence a cash tender offer to acquire all of the issued and outstanding shares of Day One’s common stock for $21.5 per share in cash, representing a premium of 68.23% from the stock’s last close.

Company Profile:

Day One is a U.S.-based biopharmaceutical company that develops and commercializes targeted therapies for genetically defined cancers, with a focus on pediatric oncology. The company is headquartered in Brisbane, California.

Servier is a France-based pharmaceutical company that develops and markets medicines, with a focus on cardiology, oncology, neurology, and venous diseases. The company operates in more than 130 countries.

Deal Details and Timeline:

The deal is expected to close in the second quarter of 2026.

Servier plans to finance the deal using its existing cash and investments.

Day One was advised on financial matters by Centerview Partners and received legal advice from Fenwick & West. Servier received financial guidance from Goldman Sachs Bank Europe SE, while Baker McKenzie acted as its legal advisor.

The purchase price represents 13.92 times the sales of Day One.

Deal Metrics:

For an in-depth look at this M&A transaction, please visit our Deal Metrics page here:

Deal Metrics for the acquisition of Day One Biopharmaceuticals, Inc. (DAWN) by Servier

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart of the merger from announcement through eventual completion or failure.
• Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
• News and SEC filings.
• A history of deal updates.
• And a whole lot more.

Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article